JPWO2023042888A5 - - Google Patents

Info

Publication number
JPWO2023042888A5
JPWO2023042888A5 JP2023548506A JP2023548506A JPWO2023042888A5 JP WO2023042888 A5 JPWO2023042888 A5 JP WO2023042888A5 JP 2023548506 A JP2023548506 A JP 2023548506A JP 2023548506 A JP2023548506 A JP 2023548506A JP WO2023042888 A5 JPWO2023042888 A5 JP WO2023042888A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
nmda
cognitive impairment
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548506A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2023042888A1 (https=
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2022/034602 external-priority patent/WO2023042888A1/ja
Publication of JPWO2023042888A1 publication Critical patent/JPWO2023042888A1/ja
Publication of JPWO2023042888A5 publication Critical patent/JPWO2023042888A5/ja
Pending legal-status Critical Current

Links

JP2023548506A 2021-09-15 2022-09-15 Pending JPWO2023042888A1 (https=)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021150246 2021-09-15
JP2022128639 2022-08-12
PCT/JP2022/034602 WO2023042888A1 (ja) 2021-09-15 2022-09-15 認知機能低下、または過体重もしくは肥満症を処置することに用いるための医薬組成物

Publications (2)

Publication Number Publication Date
JPWO2023042888A1 JPWO2023042888A1 (https=) 2023-03-23
JPWO2023042888A5 true JPWO2023042888A5 (https=) 2025-10-02

Family

ID=85602989

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548506A Pending JPWO2023042888A1 (https=) 2021-09-15 2022-09-15

Country Status (4)

Country Link
US (1) US20250281474A1 (https=)
EP (1) EP4403185A4 (https=)
JP (1) JPWO2023042888A1 (https=)
WO (1) WO2023042888A1 (https=)

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2436261B2 (de) 1974-07-27 1976-11-25 Bayer Ag, 5090 Leverkusen Elektrochemische gasdetektoren
DK146787A (da) 1987-03-23 1988-09-24 Ferrosan Heterocykliske forbindelser, deres fremstilling og anvendelse
HU221425B (en) 1990-11-06 2002-10-28 Yamanouchi Pharma Co Ltd Condensed pyrazine derivatives, process for their production and pharmaceutical preparations containing these compounds
US5639751A (en) 1990-12-21 1997-06-17 Cyogyszerkutato Intezet Kft N-acyl-2,3-benzodiazepine derivatives for treating acute and chronic neurodegenerative disorders
FR2711993B1 (fr) 1993-11-05 1995-12-01 Rhone Poulenc Rorer Sa Médicaments contenant des dérivés de 7H-imidazol[1,2-a]pyrazine-8-one, les nouveaux composés et leur préparation.
EP0743945B1 (en) 1994-02-11 2002-03-06 Novo Nordisk A/S Heterocyclic compounds and their preparation and use
DK0784054T3 (da) 1994-09-27 2002-03-25 Yamanouchi Pharma Co Ltd 1,2,3,4-tetrahydroquinoxalinderivater og deres anvendelse som glutamatreceptorantagonister
WO1996015099A1 (en) 1994-11-09 1996-05-23 Novo Nordisk A/S Heterocyclic compounds, their preparation and use
AUPN842196A0 (en) 1996-03-05 1996-03-28 Fujisawa Pharmaceutical Co., Ltd. New compound
DE19643037A1 (de) 1996-10-18 1998-04-23 Boehringer Ingelheim Kg Neue Oxadiazole, Verfahren zu ihrer Herstellung sowie deren Verwendung als Arzneimittel
HUP9701325A1 (hu) 1997-07-31 2000-08-28 Gyógyszerkutató Intézet Kft. Új 2,3-benzodiazepin-származékok
UA67749C2 (uk) 1997-08-12 2004-07-15 Егіш Дьйодьсердьяр Рт. Похідна 8-заміщеного-9н-1,3-діоксол/4,5-h//2,3/бензодіазепіну з властивостями амра/каїнатного антагоніста, спосіб одержання похідних, фармацевтична композиція (варіанти), спосіб її одержання та спосіб лікування
ES2320973T3 (es) 2000-06-12 2009-06-01 EISAI R&D MANAGEMENT CO., LTD. Compuestos de 1,2-dihidropiridina, procedimiento para su preparacion y uso de los mismos.
EP1491211A4 (en) 2002-03-29 2010-01-13 Astellas Pharma Inc DRUG AGAINST GLIOBLASTOMA
GB0405034D0 (en) * 2004-03-05 2004-04-07 Novartis Ag Organic compounds
AU2006232517A1 (en) * 2005-04-04 2006-10-12 Eisai R&D Management Co., Ltd. Dihydropyridine compounds and compositions for headaches
WO2008111590A2 (en) * 2007-03-05 2008-09-18 Eisai R & D Management Co., Ltd. Ampa and nmda receptor antagonists for neurodegenerative diseases
EP2338492A1 (en) * 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer

Similar Documents

Publication Publication Date Title
Trivedi et al. Medication augmentation after the failure of SSRIs for depression
Tzschentke Glutamatergic mechanisms in different disease states: overview and therapeutical implications–an introduction
KR100797603B1 (ko) 섬유근육통을 치료하기 위한 도파민 ｄ2/ｄ3 수용체작용제의 사용
US5840708A (en) Administration of oligonucleotides antisense to dopamine receptor MRNA for diagnosis and treatment of Neurological pathologies
Krahn et al. Narcolepsy: new understanding of irresistible sleep
JP2004504376A5 (https=)
BR0009539A (pt) composto, composição farmacêutica, método para tratamento ou prevenção de uma doença ou distúrbio associado com agonismo patogênico, agonismo inverso ou antagonismo do receptor gaba a, uso de um composto, método para localizar receptores gaba a em uma amostra de tecido, método para alterar a atividade transdutora de sinal de receptores gaba a, método para o tratamento ou prevenção de distúrbios psicológicos associados com modulação do complexo receptor gaba a, e, processo para a preparação de um composto
ES2564187T3 (es) Agentes de modulación de glutamato en el tratamiento de trastornos mentales
JPWO2023042888A5 (https=)
JP2010530867A (ja) うつ病の治療
Mostaghim et al. Endothelial potentiation of relaxation response to beta adrenoceptor blocking agents.
WO2000056315A1 (en) Treatment of pain
Ryan Characterization of cortical spindles in DBA/2 and C57BL/6 inbred mice
JP2002539251A (ja) 治療薬に伴う体重増加を調節する方法
Lee et al. Neuroleptic malignant syndrome associated with the use of risperidone, an atypical antipsychotic agent
KR20010113847A (ko) 수면 무호흡증 치료 방법
EP2665474A1 (en) Neramexane for the treatment or prevention of tinnitus related with stress or acute hearing loss
Burgess et al. Cardiotoxicity of antidepressant drugs
US5652270A (en) Pharmaceutical compositions containing bicycloheptane ether amines and a process for the preparation thereof
Shelton et al. Simulated Abuse of Tybamate in Man: Failure to Demonstrate Withdrawal Reactions
CN119730840A (zh) 用于治疗重度抑郁症的1-(萘-2-基)-3-氮杂双环[3.1.0]己烷
WO2000056321A1 (en) Treatment of hyperactivity disorders
Goldenberg Fibromyalgia, chronic fatigue, and myofascial pain syndromes
Prager Angina pectoris: effective therapy once daily
Maizels The clinician's approach to the management of headache